Research
Energy balance
The cardiovascular benefits of dual GLP-1/GIP receptor agonists like tirzepatide remain uncertain.
Further research is needed to clarify the cardiovascular benefits of tirzepatide.
StrongQualifiesmedium confidence
Whether cardiovascular benefits will be found with dual GLP-1/GIP receptor agonists remains uncertain.
Why this rating
The claim is based on ongoing research and trials.
Source
Cardiovascular effects of tirzepatide
Priya Sumithran et al. · Journal of Endocrinology · 2025
DOI 10.1530/joe-24-0259
otherCited 6×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide demonstrates unprecedented efficacy for glycaemic control, reductions in body weight, and improvements in blood pressure and lipid profile compared with placebo and GLP-1 receptor agonists.Strong
- Clinical trials of tirzepatide have demonstrated cardiovascular safety in high-risk patients.Strong
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →